Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence.

Zhao XZ, Métifiot M, Kiselev E, Kessl JJ, Maddali K, Marchand C, Kvaratskhelia M, Pommier Y, Burke TR Jr.

Molecules. 2018 Jul 26;23(8). pii: E1858. doi: 10.3390/molecules23081858.

2.

HIV-1 Integrase Inhibitors That Are Broadly Effective against Drug-Resistant Mutants.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01035-18. doi: 10.1128/AAC.01035-18. Print 2018 Sep.

PMID:
29987149
3.

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants.

Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH.

Retrovirology. 2018 May 16;15(1):37. doi: 10.1186/s12977-018-0420-7.

4.

Fabrication of Reduction-Sensitive Amphiphilic Cyclic Brush Copolymer for Controlled Drug Release.

Tu XY, Meng C, Zhang XL, Jin MG, Zhang XS, Zhao XZ, Wang YF, Ma LW, Wang BY, Liu MZ, Wei H.

Macromol Biosci. 2018 Jul;18(7):e1800022. doi: 10.1002/mabi.201800022. Epub 2018 May 10.

PMID:
29745057
5.

Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase.

Boyer PL, Smith SJ, Zhao XZ, Das K, Gruber K, Arnold E, Burke TR Jr, Hughes SH.

J Virol. 2018 Jun 13;92(13). pii: e02203-17. doi: 10.1128/JVI.02203-17. Print 2018 Jul 1.

PMID:
29643235
6.

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.

Zhao XZ, Smith SJ, Maskell DP, Métifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

J Med Chem. 2017 Sep 14;60(17):7315-7332. doi: 10.1021/acs.jmedchem.7b00596. Epub 2017 Aug 10.

7.

Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets.

Lu X, Nowicka U, Sridharan V, Liu F, Randles L, Hymel D, Dyba M, Tarasov SG, Tarasova NI, Zhao XZ, Hamazaki J, Murata S, Burke TR Jr, Walters KJ.

Nat Commun. 2017 Jun 9;8:15540. doi: 10.1038/ncomms15540.

8.

Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.

Zhao XZ, Hymel D, Burke TR Jr.

Bioorg Med Chem. 2017 Oct 1;25(19):5041-5049. doi: 10.1016/j.bmc.2017.02.063. Epub 2017 Feb 28.

PMID:
28285924
9.

Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain.

Zhao XZ, Hymel D, Burke TR Jr.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):5009-5012. doi: 10.1016/j.bmcl.2016.08.098. Epub 2016 Sep 2.

10.

Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.

Métifiot M, Johnson BC, Kiselev E, Marler L, Zhao XZ, Burke TR Jr, Marchand C, Hughes SH, Pommier Y.

Nucleic Acids Res. 2016 Aug 19;44(14):6896-906. doi: 10.1093/nar/gkw592. Epub 2016 Jul 1.

11.

Analysis of the prognostic risk factors of idiopathic membranous nephropathy using a new surrogate end-point.

Zhang BO, Cheng M, Yang M, Han S, Zhang YH, Shi HG, Zhu L, Zhao XZ.

Biomed Rep. 2016 Feb;4(2):147-152. Epub 2015 Dec 11.

12.

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases.

Zhao XZ, Smith SJ, Maskell DP, Metifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

ACS Chem Biol. 2016 Apr 15;11(4):1074-81. doi: 10.1021/acschembio.5b00948. Epub 2016 Feb 5.

13.

6,7-Dihydroxyisoindolin-1-one and 7,8-Dihydroxy-3,4-Dihydroisoquinolin- 1(2H)-one Based HIV-1 Integrase Inhibitors.

Zhao XZ, Metifiot M, Smith SJ, Maddali K, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Curr Top Med Chem. 2016;16(4):435-40. Review.

PMID:
26268341
14.

HIV integrase inhibitors block replication of alpha-, beta-, and gammaherpesviruses.

Yan Z, Bryant KF, Gregory SM, Angelova M, Dreyfus DH, Zhao XZ, Coen DM, Burke TR Jr, Knipe DM.

MBio. 2014 Jul 1;5(4):e01318-14. doi: 10.1128/mBio.01318-14.

15.

4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1.

Zhao XZ, Smith SJ, Métifiot M, Marchand C, Boyer PL, Pommier Y, Hughes SH, Burke TR Jr.

J Med Chem. 2014 Jun 26;57(12):5190-202. doi: 10.1021/jm5001908. Epub 2014 Jun 16. Erratum in: J Med Chem. 2014 Aug 14;57(15):6885.

16.

Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

Zhao XZ, Smith SJ, Métifiot M, Johnson BC, Marchand C, Pommier Y, Hughes SH, Burke TR Jr.

J Med Chem. 2014 Feb 27;57(4):1573-82. doi: 10.1021/jm401902n. Epub 2014 Feb 10.

17.

6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.

Zhao XZ, Maddali K, Smith SJ, Métifiot M, Johnson BC, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7309-13. doi: 10.1016/j.bmcl.2012.10.088. Epub 2012 Oct 27.

18.

Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.

Métifiot M, Maddali K, Johnson BC, Hare S, Smith SJ, Zhao XZ, Marchand C, Burke TR Jr, Hughes SH, Cherepanov P, Pommier Y.

ACS Chem Biol. 2013 Jan 18;8(1):209-17. doi: 10.1021/cb300471n. Epub 2012 Dec 24.

19.

Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.

Zhao XZ, Maddali K, Metifiot M, Smith SJ, Vu BC, Marchand C, Hughes SH, Pommier Y, Burke TR Jr.

Chem Biol Drug Des. 2012 Feb;79(2):157-65. doi: 10.1111/j.1747-0285.2011.01270.x. Epub 2011 Dec 22.

PMID:
22107736
20.

MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

Métifiot M, Johnson B, Smith S, Zhao XZ, Marchand C, Burke T, Hughes S, Pommier Y.

Antimicrob Agents Chemother. 2011 Nov;55(11):5127-33. doi: 10.1128/AAC.05288-11. Epub 2011 Aug 29.

Supplemental Content

Loading ...
Support Center